New practice for follow-up information on adverse reaction reports

29 September 2017

The Danish Medicines Agency has introduced a new practice for the processing of pharmaceutical companies’ requests for follow-up information on reports of suspected adverse reactions.

We need to strengthen the practice to ensure that we only receive follow-up requests that are relevant and necessary for pharmacovigilance reasons.

Pharmaceutical companies are encouraged not to request follow-up information, unless the information is considered relevant and necessary for pharmacovigilance and patient safety.

The companies must give a specific reason for each follow-up request, and the request must be relevant, necessary and well-founded in each case. The Danish Medicines Agency will reject follow-up requests from pharmaceutical companies if the criteria for a follow-up request are not met.

Read more about the processing of follow-ups, requirements for the individual requests and our guideline for follow-ups

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.


You have to accept marketing cookies to watch video content

Update consent